Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AcelRx Pharmaceuticals, Inc. (ACRX)

0.6925   -0.027 (-3.81%) 03-24 11:36
Open: 0.718 Pre. Close: 0.7199
High: 0.718 Low: 0.67
Volume: 50,192 Market Cap: 6(M)

Technical analysis

as of: 2023-03-24 11:58:45 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.45     One year: 1.95
Support: Support1: 0.56    Support2: 0.47
Resistance: Resistance1: 1.24    Resistance2: 1.66
Pivot: 0.89
Moving Average: MA(5): 0.68     MA(20): 1
MA(100): 1.89     MA(250): 3.6
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 18.5     %D(3): 15.8
RSI: RSI(14): 23.2
52-week: High: 7.59  Low: 0.18
Average Vol(K): 3-Month: 224 (K)  10-Days: 561 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ACRX ] has closed above bottom band by 29.1%. Bollinger Bands are 0.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.75 - 0.75 0.75 - 0.75
Low: 0.66 - 0.67 0.67 - 0.67
Close: 0.71 - 0.72 0.72 - 0.73

Company Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Headline News

Tue, 21 Mar 2023
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 - Yahoo Finance

Tue, 14 Mar 2023
Is AcelRx Pharmaceuticals Inc (ACRX) Stock a Smart Investment Tuesday? - InvestorsObserver

Tue, 14 Mar 2023
AcelRx Pharmaceuticals Shares Rise Premarket on Dsuvia Sale >ACRX - MarketWatch

Wed, 01 Mar 2023
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On ... - PR Newswire

Thu, 29 Dec 2022
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript - Yahoo Finance

Tue, 27 Dec 2022
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. -23 (M)
Shares Float 0 (M)
% Held by Insiders 8.2e+006 (%)
% Held by Institutions 7.35e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -5.03e+006
EPS Est Next Qtl -0.24
EPS Est This Year -1.13
EPS Est Next Year -0.94
Book Value (p.s.) 3.77
Profit Margin (%) 3
Operating Margin (%) 111.2
Return on Assets (ttm) -2
Return on Equity (ttm) 102.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) -22.5
Sales Per Share 0
EBITDA (p.s.) -2.91667e+006
Qtrly Earnings Growth -3.021e+007
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0.18
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 666620
Forward Dividend 534860
Dividend Yield 96262800%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.